The Latest Cardiac and Vascular News
Budiodarone shown in Phase 2 to reduce atrial fibrillation symptoms and long episodes of atrial fibrillation (LEAF) FDA gives guidance on steps necessary to gain approval and incorporate wearable AF monitoring devices into label for budiodarone Five granted US patents align with FDA’s…
ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host a live demonstration of the GenesisX Robotic System at this year’s Heart Rhythm Symposium (HRS), taking place April 24 – 27 […]
Advancing PFA through a science-led, portfolio-driven approach to innovation MARLBOROUGH, Mass.–(BUSINESS WIRE)–CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, is excited to announce its featured presence at Heart Rhythm 2025 in San Diego, where the company will showcase the latest advancements and clinical progress […]
Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in presentations and in a live case transmission HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that its Nanosecond PFA technology will […]
MINNEAPOLIS–(BUSINESS WIRE)–Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce that it has commenced the VISABL-VT clinical trial by completing the first-in-human ventricular ablation guided by real-time MRI with the Company’s NorthStar Mapping System. The procedure was performed by the team at the Amsterdam University Medical Centre (AUMC), ranked […]
NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an industry-sponsored satellite symposium at the Heart Rhythm Society (“HRS”) 2025 Annual Meeting, taking place April 24–27, 2025, in San Diego, California featuring recent advancements in the Company’s atrioventricular interval modulation (“AVIM”) therapy program. The April 25th, 6:45 am PT symposium titled “The Future of Cardiac Pacing: Unlocking the Potential of Atrioventricular Interval Modulation (AVIM) Therapy” will convene leading electrophysiologists, hypertension and heart failure specialists to discuss the unmet need in hypertension, AVIM therapy mechanism of action, and growing body of clinical evidence supporting this novel therapy for the treatment of patients with uncontrolled hypertension who have increased cardiovascular risk with or without an indication for a pacemaker.
WASHINGTON, April 23, 2025 /PRNewswire/ — Today, the Heart Rhythm Society (HRS) released a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients. AF, the most…
Eight presentations, including late-breaking science, live cases, and a landmark symposium CARDIFF-BY-THE-SEA, Calif., April 23, 2025 /PRNewswire/ — Field Medical Inc., a leader in cardiac pulsed field ablation (PFA) technology, announced today its FieldForce™ Ablation System will be…
Company to spotlight ASSURE WCD performance and expanded clinical applicationsKIRKLAND, Wash., April 23, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, announced today it will exhibit at Heart Rhythm 2025, the annual meeting of the Heart Rhythm Society (HRS), taking place April 24-27 at the San Diego Convention Center. This marks Kestra’s first major industry showcase following its successful IPO earlier this year. Kestra will debut an immersive in-booth experience designed to bring the ASSURE® system to life—demonstrating how this innovative technology is redefining protection for patients at risk of sudden cardiac arrest. By combining lifesaving defibrillation therapy with intuitive, intelligent, and connected diagnostic and patient support capabilities, the ASSURE system is a key part of a broader vision for a holistic cardiac care ecosystem that supports patients and providers across the recovery journey. “Our presence at Heart Rhythm 2025 comes at a pivotal time for Kestra,” said Brian Webster, President and Chief Executive Officer of Kestra. “Following our IPO, we’re moving forward with increasing momentum—and this year’s HRS meeting is an opportunity to demonstrate how the ASSURE system goes beyond protection to offer a smarter, more connected recovery experience for both patients and care teams.” In addition to exhibiting, Kestra will also present new real-world clinical data highlighting the impact of the ASSURE system. Kestra is also proud to sponsor the Women in EP Luncheon for the fourth consecutive year—underscoring its ongoing commitment to leadership, innovation, and equity in cardiovascular care. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. Media contactRhiannon Pickusrhiannon.pickus@kestramedical.com Investor contactNeil Bhalodkarneil.bhalodkar@kestramedical.com
CARDIFF-BY-THE-SEA, Calif., April 22, 2025 /PRNewswire/ — Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of $40 million in Series A financing. The round includes $20 million in new capital and the conversion of $20…
